PPAR-γ在肥胖及其并发症中的作用概述

Overview of PPAR-γand Its Role in Obesity and Metabolic Syndrome

肥胖与胰岛素抵抗,葡萄糖耐受不良,高血压和血脂异常等并发症,统称为代谢综合征(MetS)。是全球面临的最具挑战性的健康问题之一。饮食和生活方式的变化是肥胖增长的主要原因。目前,肥胖治疗方法有很多,主要针对脂蛋白,血压或人体测量指标进行对症治疗。过氧化物酶体增殖物激活受体(PPARs)参与脂质和脂蛋白水平的代谢调节,对甘油三酯(TG),血糖和腹部肥胖具有一定调节作用。其中PPAR-γ在治疗肥胖及其并发症的研究最为广泛,PPAR-α和γ的合成配体纤维酸和噻唑烷二酮已用于患有2型糖尿病和糖尿病前期胰岛素抵抗的患者中,具有显着改善血糖水平的作用。本文就PPAR-γ在肥胖及其并发症中的治疗作用及其机制进行综述。

Obesity and insulin resistance,glucose intolerance,high blood pressure and dyslipidemia are called metabolic syndrome(MetS).It is one of the most challenging health problems facing the world.Changes in diet and lifestyle are the main reason for obesity growth.At present,there are many treatment methods for obesity,mainly for symptomatic treatment of lipoprotein,blood pressure or anthropometric indicators.Peroxisome proliferator-activated receptors(PPARs)are involved in the metabolic regulation of lipid and lipoprotein levels,and have certain regulatory effects on triglycerides(TG),blood glucose,and abdominal obesity.Among them,PPAR-γ is the most widely studied in the treatment of obesity and its complications.The synthetic ligands of PPAR-α and γ,fibric acid and thiazolidinedione,have been used in patients with type 2 diabetes and prediabetes insulin resistance.Significantly improve the effect of blood sugar levels.This article reviews the therapeutic effect and mechanism of PPAR-γ in obesity and its complications.